Filing Flows › Kura Oncology (KURA) › Q2 2025
Kura Oncology (KURA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Kura Oncology (KURA) reported revenue of $15.3M for the second quarter 2025 (Q2 2025) and +8% from the quarter before. Operating margin was -475.3%, net loss $66.1M (432.5% of revenue).
Kura Oncology, Q2 2025: revenue $15.3M, operating margin -475.3%, net loss $66.1M, operating cash flow −$28.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.3M | +8% | — |
| Operating profit | −$72.7M | — | — |
| Net earnings | −$66.1M | — | — |
| Operating cash flow | −$28.8M | — | — |
What changed
Revenue was $15.3M in Q2 2025, up 8% from the previous quarter.
Operating costs exceeded revenue by $72.7M, an operating margin of -475.3%. The quarter ended with a net loss of $66.1M, wider than the previous quarter's $57.4M loss.
Operating cash flow was −$28.8M. Non-cash charges added back $224K of depreciation and $6.9M of share-based compensation. Working capital and other items added $30.2M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$30.2M.
Questions
What was Kura Oncology's revenue in the second quarter 2025?
Kura Oncology (KURA) reported revenue of $15.3M for the second quarter 2025 (Q2 2025) and +8% from the quarter before.
Was Kura Oncology profitable in the second quarter 2025?
Operating loss was $72.7M (-475.3% of revenue) and net loss $66.1M.
Source: Kura Oncology 10-Q on SEC EDGAR.